Abbott Spinal Cord Stimulator Trial: A New Hope for Chronic Back Pain Patients

The Food and Drug Administration (FDA) has recently approved Abbott's spinal cord stimulation (SCS) devices for the treatment of chronic back pain in individuals who are not suitable or have no option to undergo surgery. This groundbreaking approval is based on the results of the largest randomized controlled trial for SCS in people with chronic back pain, known as the DISTINCT study.

The DISTINCT study, which has been published under clinical trial registration number NCT0447987, involved a large population of patients who suffered from chronic back pain and had exhausted all other treatment options. The study aimed to assess the efficacy and safety of Abbott's SCS devices in these individuals, and the results were nothing short of remarkable.

Abbott's SCS program includes both recharge-free Proclaim SCS family and rechargeable Eterna SCS platform devices. With this approval, patients who are not eligible for surgery or have chronic back pain can now benefit from a minimally invasive procedure that has shown to provide significant relief from their symptoms.

The FDA's approval is a significant milestone in the development of innovative treatments for chronic back pain. Abbott's SCS devices offer a new hope for individuals who have been living with persistent pain and limited mobility, as well as those who are hesitant or unable to undergo surgical intervention.

In conclusion, the approval of Abbott's spinal cord stimulation devices for chronic back pain is a major breakthrough in the field of pain management. With its recharge-free and rechargeable platforms, this technology has the potential to revolutionize the way we treat chronic back pain, providing patients with a safer and more effective alternative to traditional surgical procedures.

Abbott spinal cord stimulator trial